Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome

Graziano Grugni, Antonino Crinò, Sara Pagani, Cristina Meazza, Fabio Buzi, Teresa De Toni, Luigi Gargantini, Alba Pilotta, Giovanni B. Pozzan, Giorgio Radetti, Letizia Ragusa, Alessandro Salvatoni, Alessandro Sartorio, Mauro Bozzola

Research output: Contribution to journalArticlepeer-review


The aetiology of impaired growth hormone (GH) secretion in Prader-Willi syndrome (PWS) remains controversial due to the common occurrence of obesity. To further clarify whether suboptimal GH secretion in PWS is an artefact of excess weight, we evaluated both GH immunological activity and GH bioactivity after arginine administration in 23 non-obese PWS patients [seven females, aged 6.9±0.9 years, body mass index (BMI) SDS 0.63±0.26], in comparison with a control group of 32 healthy subjects, matched for age, gender and BMI (10 females, aged 7.9±0.3 years, BMI SDS 0.21±0.20). Serum GH concentration was measured with a time-resolved immunofluorometric assay (IFMA), while GH bioactivity was evaluated by the Nb2 cell bioassay. Serum IGF-I concentrations were measured by double-antibody RIA. GH mean peak after pharmacological stimulation was significantly lower in PWS individuals compared with controls when measured either by IFMA (6.05±1.23 μg/L vs. 23.7±1.06 μg/L, p

Original languageEnglish
Pages (from-to)477-481
Number of pages5
JournalJournal of Pediatric Endocrinology and Metabolism
Issue number7-8
Publication statusPublished - Aug 1 2011


  • GH bioactivity
  • GH deficiency
  • obesity
  • Prader-Willi syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome'. Together they form a unique fingerprint.

Cite this